I am an investor

Read more

I want to know more about Cantargia's research

Read more

I want to know more about Cantargia as a company

Read more

CEO presentation

To the presentation (in Swedish)

Presentation at ASCO 2019, follow up articles and interviews

Read more

Cantargia interview at EFN after ASCO

To the interview (in Swedish)

Cantargia partners up with pioneer within biotech industry

Read more

A brief introduction to Cantargia

To the interview
Press releases

2020-07-31 (R) New number of shares and votes in Cantargia

2020-06-23 (R) Cantargia strengthens management team with VP Regulatory Affairs and VP CMC

2020-06-22 (R) Cantargia presents new preclinical data on CAN04 at the 2020 AACR Annual Meeting

(R) = Regulatory press releases

”During 2018, we concluded the first very important part of the clinical development of CAN04 and presented patient data that strengthens our hopes that CAN04 can become an important part of tomorrow’s cancer treatment”

Göran Forsberg
CEO Cantargia
Analysis

2020-05-28, Nordea analysis of Cantargia

2020-05-06, Edison analysis of Cantargia

2020-03-10, Aktiespararna analysis of Cantargia (In Swedish)

2020-02-28, Nordea analysis of Cantargia

Presentations

2020-06-22, Poster presentation 2020 AACR Annual Meeting
The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy

2020-06-22, Poster presentation 2020 AACR Annual Meeting
Zebrafish patient tumor-derived xenograft models used for pre-clinical evaluation of CAN04 for lung and pancreatic cancer

2020-06-02, Presentation, Redeye Growth Day, Stockholm

2020-05-26, Presentation, ABGSC Life Science Summit, Stockholm

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2020 · Cantargia AB